0 CHECKOUT

PRODUCT FILTERS

REGION

38
31
29
27
20

COUNTRY

13
10
8
6
3

PRICE

42
78
114
166

PUBLISHED

5
11
50
166

PRODUCT TYPE

159
2
1
1
1
1
1

Generic Drugs

The global generics market is fast growing, driven by demand for cost-effective medicines and new availability of high value products. By now there are 17 generic companies with revenues in excess of US$1 billion, while there were only 12 in 2008/09.

The reports, books, and subscriptions listed under Research and Markets’ Generic Drugs category cover every aspect of this industry, such as market trends, forecasts, drivers and restraints, etc. They will allow you to identify business opportunities and assess the strategies of the major players. You can also investigate the latest international and national patent opportunities across a vast number of INNs (international non-proprietary names), taking into account key concerns such as expiry dates, national regulations, etc.

Key players featured in our publications includes Teva Pharmaceutical, Mylan, Sandoz, Watson Pharmaceuticals, Greenstone, Par Pharma, Hospira, Apotex, Mallinckrodt, Dr. Reddy's, and more. Show Less
Read more

Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

GBI Research, the leading business intelligence provider, has released its latest research “Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent...

Published:  May 2012
Price:  From

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar Summary GBI...

Published:  June 2012
Price:  From

Orphan Disease Therapeutic Disorders to 2018 - Emerging utics in GenAgents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity

GBI Research, the leading business intelligence provider, has released its latest research, “Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong...

Published:  May 2012
Price:  From

Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets

GBI Research, a leading business intelligence provider, has released its latest research “Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing...

Published:  April 2012
Price:  From

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven...

Published:  April 2012
Price:  From

Assessment of the Japan Generics Industry

While Japan is the second largest pharma market globally, it has a very low penetration rate of generic drugs The country’s government has set an ambitious goal to enhance the generics penetration to...

Published:  March 2012
Price:  From

Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market

GBI Research, the leading business intelligence provider, has released its latest research “Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics...

Published:  April 2012
Price:  From

Branded Generics in South East Asia: Current and Future Opportunities

With its fast-growing, young population and projected pharmaceutical sales in excess of $20 billion in 2014, countries in the Association of South East Asian Nations (ASEAN) represent a great opportunity...

Published:  April 2012
Price:  From

Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies

GBI Research's report ""Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies"" finds that the global herpes market is an attractive...

Published:  April 2012
Price:  From

Top Ten ANDA / PARA-IV / API Opportunities To Be Targeted By Generic or Active Pharmaceutical Ingredient Companies

Top Ten ANDA / PARA-IV / API Opportunities To Be Targeted By Generic or Active Pharmaceutical Ingredient Companies Product Selection is one of the most crucial aspects of growth strategy for a generic...

Published:  March 2012
Price:  From

Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from...

Published:  February 2012
Price:  From

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

GBI Research, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to...

Published:  January 2012
Price:  From

Japan Generics Market Analysis

Japan is the world’s second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it However, worried over rising healthcare expenses...

Published:  February 2012
Price:  From

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

GBI Research, the leading business intelligence provider, has released its latest research “Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of...

Published:  January 2012
Price:  From

Generic Drugs Market in Japan

Reports can include market size information, market access strategies, market share, export and import information, market analysis, market trends, competition, domestic production, best sales prospects,...

Published:  November 2011
Price: 

Multi-therapy Drugs: Opportunities for Generics & Biosimilars

Highly-detailed analysis, outlook & forecasts of 24 leading drugs which are indicated for a range of critical conditions Targeting multiple conditions is likely to increase a drug's potential target...

Published:  October 2011
Price:  From

Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape

Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape Summary GBI Research’s...

Published:  October 2011
Price:  From

Global Generics

Global Generics market was valued at US$123 billion in 2010, and has been estimated to reach US$ 180 billion by 2014, at a CAGR of 10 6% during 2011-14 Generics market remains a major growth area in...

Published:  August 2011
Price:  From

The Impact of Generics on Pharmaceutical Growth Opportunities - A Growing Threat that Offers Future Opportunities

While generic penetration has been on the rise in the major developed markets for some time, the current and continuing difficult economic environment is stimulating political and payer actions to accelerate...

Published:  October 2011
Price:  From

Hospital Injectable Drugs: Future Prospects for Generics & Biosimilars

The generic injectables sector exceeds US$11 2 billion and numerous high-value injectable products will face patent expiry in major markets over the next decade This critical new report evaluates the...

Published:  July 2011
Price:  From
Loading Indicator

Our Clients